Skip to main content

Table 5 Hypofractionated radiotherapy trials on primary and metastatic hepatic tumors

From: Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer

Author Lesions (HCC/CCC/Metastatic tumor) Treatment (prescription dose/fractionated frequency/isodose) Median follow-up months (range) Local control rate * Survival rate Median tumor volume cc (range) Toxicity
Takeda [9] 2008 16/0/0 35(20-50) gy/5-9/80% 20.4 (8.1-33.1) 100% at 1 year, 94% at 2 year 100% at 2 year 13.6 (3.4-72) No SE
TSE [11] 2008 31/10/0 36 (24-54) gy/6/NA 17.6 (10.8-39.2) 65% at 1 year (CR 5%, PR 44%, SD 42%) 51% at 1 year (HCC 48% at 1 year) 173 (9-1913) No SE 5 patients (12%); grade 3 (liver)
Present 42/0/0 33 (30-39) gy/3/80% 28.7 (8.4-49.1) 72.0, 67.5% at 1 and 2, 3 and 4 year (CR 60%, PR 26%, SD 14%) 92.9/77.3/58.6/58.6% at 1, 2, 3, 4 year 15.4 (3.0-81.8) 1 patient (2%); grade 4 (liver)
  1. Abbreviations: HCC, hepatocellular carcinoma; CCC, cholangiocarcinoma; NA, non-available
  2. *Local control rates are in-field progression free rates or tumor responses according to RECIST criteria.